Role of Pancreatic Triglyceride Content in Beta-cell Function: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Role of Pancreatic Triglyceride Content in Beta-cell Function (NCT00602953), a registered phase not stated study. The primary outcome is Pancreatic and Liver Fat.

2. Clinical Question

3. Trial Design

The study is registered as NCT00602953 and is titled “Role of Pancreatic Triglyceride Content in Beta-cell Function.” The sponsor is the University of Texas Southwestern Medical Center. The registry lists enrollment of 101 and status as completed. The recorded study start is 2007-09, and primary completion is 2012-08.

This is not a randomized comparison. The record says no intervention was planned, does not state allocation, and describes several participant groups rather than treatment arms in a controlled trial. The groups include healthy volunteers, people with pre-diabetes, overweight volunteers, and participants with type 1 or type 2 diabetes. Their descriptions reflect different weight and glucose-status profiles. The registry record does not establish that each group was recruited or assessed under an identical protocol beyond the information in the outcome description.

The primary outcome is pancreatic and liver triglyceride content, expressed as a percent and measured using magnetic resonance spectroscopy. The timeframe is within 1 month after screening. The record lists four outcome measures, but gives only the primary outcome details in the information available for this summary. The registry record does not report a statistical analysis plan, a sample-size justification, or the results for the primary outcome. It also does not report analyses of whether pancreatic fat predicts insulin secretion.

Because allocation is not stated and there is no planned intervention, the study should be read as an investigation of measured characteristics and their potential relationships, not as a trial estimate of a treatment effect. Differences among participant groups may be descriptive; they do not by themselves identify a causal effect.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Pancreatic and Liver Fat, measured over Within 1 month after screening visit..

The primary endpoint is pancreatic and liver triglyceride, or fat, content measured by magnetic resonance spectroscopy. The registry gives the unit as percent, the summary measure as median, and the dispersion measure as interquartile range. Measurements were to be made within 1 month after the screening visit.

These measurements address the study’s central question about whether fat accumulates in the pancreas among people with varying body mass index and glucose status. The study summary also describes an interest in whether the amount of pancreatic fat can predict residual pancreatic functional capacity, meaning insulin secretion. The listed primary endpoint, however, is fat content; it is not itself a direct measurement of insulin secretion or a reported prediction model.

Magnetic resonance spectroscopy is the measurement technique named in the record. In general, a median describes the middle of a set of measurements, while the interquartile range describes the spread of the central portion of those measurements. This pairing can communicate a typical value and variability without assuming that the data follow a symmetric distribution.

The registry record does not report the median or interquartile range for pancreatic or liver fat, nor does it provide estimates of relationships with insulin secretion. As a result, the endpoint’s definition and intended role are available, but its observed values and interpretation are not.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical information in the record is limited. The primary endpoint is defined as pancreatic and liver fat measured using magnetic resonance spectroscopy, with results intended to be summarized as medians and interquartile ranges. The registry lists no statistical analyses. It does not report a detailed analysis plan, a model, an adjustment strategy, or a sample-size justification for the study itself.

Why report a median and interquartile range?

In general, the median is the central value after measurements are ordered. Unlike the mean, it is less affected by unusually high or low observations. The interquartile range describes the spread of the middle portion of the measurements. Together, these summaries can be useful when data are skewed or contain extreme values. They do not, by themselves, show whether groups differ beyond what might be expected from sampling variability. The registry record specifies this summary approach but does not give the resulting values.

What does the measurement represent?

The endpoint concerns fat content in the pancreas and liver, measured by magnetic resonance spectroscopy. The registry describes the unit as percent and places the measurement within 1 month after screening. In general, an endpoint definition identifies what is measured, how it is expressed, and when it is assessed. Those details help readers understand what a result would represent, but they do not reveal the result itself. The record does not provide the distributions, participant-level data, or a measure of uncertainty for these measurements.

How should group comparisons be approached?

The study includes participant groups with differing descriptions of weight and glucose status. The record does not describe random allocation, and no intervention was planned. In general, comparisons across such groups are observational: a difference in measured outcomes may reflect group characteristics as well as other factors. Statistical adjustment can sometimes address measured covariates, but the registry record does not report whether adjustment was planned or performed. It also does not describe the group-specific analysis populations for the primary outcome.

The study summary raises a prediction question about pancreatic fat and residual insulin secretion. Prediction and association are not interchangeable. In general, an association describes how measurements vary together, whereas a prediction analysis evaluates how well information about one measurement forecasts another, ideally with methods that assess performance beyond the data used to fit the model. The record does not report a prediction model, its inputs, its performance, or an analysis of insulin secretion. No conclusion about prediction can therefore be drawn from the record.

What can sample-size planning say?

In general, a sample-size calculation is a planning exercise that depends on assumptions about the effect to detect, variability, significance level, allocation, and statistical method. A planning illustration is not an observed result and is not observed power. The record’s stated illustration assumptions include a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; it describes the effect to detect as a stated fraction of an observed effect. The record does not give a trial-specific sample-size justification. Since no primary outcome estimates or calculated planning values are reported in the information available, those assumptions cannot be used to characterize the study’s actual precision or ability to detect a relationship.

In general, over-dispersion means that observed variation is greater than a model assumes. If a statistical model fails to allow for that extra variation, its uncertainty estimates can be too small and its tests may appear more decisive than warranted. The registry record does not identify an over-dispersed outcome or a model for which this issue was assessed; this is a general consideration, not a reported feature of this study.

Finally, the record lists four outcome measures but reports no analyses. There are no posted estimates or inferential results to evaluate for model assumptions, multiplicity, adjustment, or robustness. Those omissions limit statistical interpretation; they do not establish that the analyses were not conducted outside the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists four outcome measures and identifies pancreatic and liver fat content as the primary outcome. It does not provide details for the other outcome measures in the record, nor does it report an analysis plan describing which outcomes were tested, in what order, or how multiplicity was addressed. No statistical analyses are listed. The registry record therefore does not establish whether any adjustment for multiple comparisons was planned or applied.

In general, testing several outcomes or comparisons can increase the chance of finding an apparently notable result by chance. A prespecified hierarchy or multiplicity adjustment can help manage that concern. Without the analysis plan and results, readers cannot determine whether multiplicity affected interpretation in this study. This is a limit on what can be concluded from the registry record, not proof that multiplicity was mishandled.

The record does not report missing-data counts, reasons for missing measurements, or methods for handling missing observations. It also does not specify the number of participants included in the primary endpoint analysis. The listed enrollment is 101, but enrollment alone does not establish how many participants contributed usable measurements or whether all outcome data were complete.

Likewise, the registry record does not define an analysis population for the primary endpoint or report exclusions from analysis. It does not state whether the analysis used all enrolled participants, only those with valid measurements, or another population. These details are important because missingness and analysis-population choices can affect the interpretation and representativeness of results.

In general, missing-data methods rely on assumptions about why values are absent. Without the amount and pattern of missingness, and without the methods used, the consequences cannot be assessed. The registry record does not report those details.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s adverse-event information lists zero serious adverse events and zero other adverse events in the groups with participants at risk: healthy volunteers, pre-diabetes, overweight, and type 2 diabetes. The corresponding at-risk counts are 15, 26, 47, and 13, respectively. Each of those groups also has zero deaths recorded. The type 1 diabetes safety group lists zero participants at risk, zero events, and zero deaths.

These are safety figures as entered in the registry, not estimates of comparative risk. There was no planned intervention and no randomized treatment comparison, so the groups should not be read as treatment arms. The zero counts mean that no events are recorded for these categories in the registry; they do not establish that no events occurred outside the reporting captured in the record or that the study could rule out uncommon harms.

The type 1 diabetes group’s zero at-risk count is especially important when interpreting its zero event counts: without participants listed at risk, those entries do not provide evidence about event frequency in that group. The registry record does not give event definitions, collection procedures, or additional detail about safety follow-up. These figures should therefore be read as registry-reported counts within the stated groups, not as a complete safety assessment.

12. What the Result Does, and Does Not, Mean

The record establishes that the study examined pancreatic and liver fat content using magnetic resonance spectroscopy in volunteers described across a range of body mass index and glucose-status profiles. It also establishes that the study summary raised a question about whether pancreatic fat could predict residual pancreatic function, described as insulin secretion. Those are the study’s aims, not findings.

The registry record does not report the observed median or interquartile range for the primary outcome, group-specific results, or analyses of insulin secretion. It therefore does not show how much pancreatic or liver fat was measured, whether measurements differed among participant groups, or whether pancreatic fat predicted functional capacity. The absence of reported estimates is not evidence of no difference or no association.

The design information also limits the kind of conclusion that could be drawn. No intervention was planned, allocation is not stated, and the groups are not a like-for-like randomized control comparison. In general, differences among observational groups do not on their own establish that one characteristic caused another. The record does not report adjustment methods or other analyses that would clarify such relationships.

The safety record lists no serious or other adverse events in the groups with participants at risk, and no deaths in the listed groups. These counts describe what is recorded; they do not establish comparative safety or rule out events beyond the record’s reporting.

In practical statistical terms, the information available describes the question, endpoint, measurement method, group structure, and safety counts, but not the outcome evidence needed to answer the research question. Any statement about the size, direction, precision, or predictive value of an observed relationship would go beyond what the registry record reports.

13. Why This Trial Matters Statistically

This study is statistically interesting because it connects a biological measurement—pancreatic fat content—with a functional question about insulin secretion. The registry frames the investigation across people with different weight and glucose-status profiles, making clear why outcome definition and participant-group interpretation matter. Its primary endpoint is a measured quantity, rather than a treatment response.

The record also illustrates an important distinction between a stated research aim and an analyzed result. The brief summary asks whether pancreatic fat can predict residual pancreatic function, but the registry lists no analyses and reports no numerical primary outcome values. A clear question is not itself evidence that the proposed relationship was observed or quantified. Without estimates and uncertainty measures, readers cannot judge the magnitude or precision of a relationship.

The observational structure is another key statistical feature. Groups with different clinical profiles can support descriptive comparisons, but without random allocation, group differences may reflect other characteristics as well. The record does not report an adjustment strategy that would help assess this issue. Reading group labels as if they were randomized treatment arms would overstate what the design can establish.

Finally, the record names a measurement method, unit, summary statistics, and timing. These choices help define what a future result would mean. Medians and interquartile ranges describe central tendency and spread, but they do not replace inferential estimates or a clear account of missing measurements and analysis populations. The record’s limited statistical reporting makes those distinctions especially important: the research question is documented, while the numerical evidence needed to evaluate it is not.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpretation is that the registry record does not report numerical results for the primary endpoint. It identifies pancreatic and liver fat content as the outcome and specifies a measurement technique, unit, summary measure, and assessment timeframe, but supplies no group-level estimates or uncertainty measures. This prevents assessment of the observed levels, variability, or differences.

The record also does not report the proposed relationship between pancreatic fat and residual insulin secretion. The brief summary describes prediction as an aim, but no predictive analysis, model, or performance estimate is listed. The primary endpoint definition alone cannot establish that this relationship was evaluated or characterize its strength.

Design details are limited. No intervention was planned, allocation is not stated, and the listed groups are not a randomized control comparison. The registry does not report adjustment methods or clarify whether the different groups were analyzed as descriptive strata or in a particular model. As a result, even if group differences were reported elsewhere, causal interpretation would require information not present in this record.

The registry record does not give the analysis population for the primary outcome, missing-data counts, reasons for missingness, or methods for handling missing observations. It lists four outcome measures but no statistical analyses, and does not state how multiple outcomes or comparisons were addressed. It also does not provide the study’s own sample-size justification.

Safety counts are reported, but the record does not give event definitions or collection procedures. The zero at-risk count for the type 1 diabetes safety group means its zero event count cannot be interpreted as evidence about event frequency in that group. These limitations concern the detail available in the registry record and should not be treated as proof about what was or was not done outside the record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Role of Pancreatic Triglyceride Content in Beta-cell Function — NCT00602953.
• Registry record last updated 2017-12-26; status last verified 2017-11.
• Results first posted 2017-12-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00602953, “Role of Pancreatic Triglyceride Content in Beta-cell Function,” is listed as completed, with enrollment of 101 and sponsorship by the University of Texas Southwestern Medical Center. The recorded study start is 2007-09 and primary completion is 2012-08. No intervention was planned, and allocation is not stated.

The primary outcome is pancreatic and liver fat content measured by magnetic resonance spectroscopy, expressed as a percent and summarized using the median and interquartile range. The planned timeframe was within 1 month after screening. The study summary also describes interest in whether pancreatic fat predicts residual pancreatic function, or insulin secretion.

The registry lists four outcome measures and no statistical analyses. It does not report the primary outcome values, prediction results, missing-data details, or a trial-specific sample-size justification. Safety groups with participants at risk have zero serious and other adverse events recorded; the type 1 diabetes group lists zero participants at risk.